MSTN and chronic kidney disease: Our findings also support this association by providing in vivo data and bringing attention to myostatin inhibition by MSTN-ASO as a targeted gene therapy, reducing myostatin levels, resulting in muscle mass, and improving functional outcomes in CKD.